Gogia A, et al. - In order to assess the long-term outcome of patients with metastatic breast cancer from developing nations, researchers performed an ambispective review of approximately 1,800 patients who were registered in breast cancer clinics between January 2012 and August 2018. They suggest this study to be the first comprehensive study of metastatic breast cancer from India. Among these, 410 (22.8%) patients with up-front metastasis were identified; additional analysis was done on 375 of the 410 patients. The patients presented at the median age of 49 years (range, 22 to 80 years), and had a median duration of symptoms of 6 months (interquartile range, 3-12 months). As per baseline receptor status, 234 patients (62.4%) were hormone receptor (HR) positive, 145 (38.6%) were human epidermal growth factor receptor positive, and 69 (18.6%) had triple-negative breast cancer. Metastasis was observed to various sites such as visceral 219 (58.4%), bone only 100 (26.7%), nonregional lymph node metastasis 21 (5.6%), brain 10 (2.7%), and others 25 (5.8%). Up-front chemotherapy was provided to approximately 309 patients (82.4%), endocrine therapy to 192 HR-positive patients (82.1%), and targeted agents to 78 human epidermal growth factor receptor–positive patients (53.8%). The cohort displayed median progression-free survival of 14.2 months, and median overall survival (OS) of 31.7 months. Multivariable Cox regression analysis revealed better OS in correlation with HR-positive disease, good performance status (0 or 1), and oligometastasis, whereas inferior OS in correlation with triple-negative breast cancer and liver and brain metastasis.